Literature DB >> 10805613

Comparison of benzodiazepines and the non-benzodiazepine agents zolpidem and zaleplon with respect to anxiolytic action as measured by increases in hypertonic NaCl-solution drinking in rats.

E Lobarinas1, J L Falk.   

Abstract

RATIONALE: In previous studies, water-deprived rats offered hypertonic 1.5% NaCl solutions to drink showed increased intakes when treated with agents known to have anxiolytic action in humans. This study explored two non-benzodiazepine (non-BZ) sedative-hypnotic agents, zolpidem and zaleplon, and compared them with three traditional BZs.
OBJECTIVES: Although many studies confirm that treatment with BZs possessing sedative-hypnotic and anxiolytic actions also produces acute increases in food and fluid ingestion in animals, zolpidem has yielded conflicting results. To help resolve this question, we compared three BZs with zolpidem and zaleplon with respect to their actions in increasing the ingestion of 1.5% NaCl solution in water-deprived rats.
METHODS: Rats were adapted to a water-deprivation schedule permitting drinking for 1 h daily. Once or twice each week, 1.5% NaCl solution was substituted for water during the drinking session and, 15 min pre-session, rats were given a drug or vehicle dose by gavage (p.o.) to delineate the dose-effect relationships for zolpidem, zaleplon, alprazolam, clonazepam, and chlordiazepoxide. Then, the dose-effect relationship for zolpidem was re-determined. A second study with two groups, using both zolpidem and clonazepam, explored whether following the dose-effect determination of a drug by a second determination affected the second relationship, and whether dose-effect determinations of either agent affected the results of the second agent investigated.
RESULTS: All agents yielded dose-related increases in 1.5% NaCl solution ingestion, except the first zolpidem determination in the first study. In the second study, all determinations yielded dose-related increases, with no indication that the set of determinations for the first agent affected those for the second agent.
CONCLUSIONS: The BZ and non-BZ agents explored yielded significant dose-effect relationships using this procedure, confirming their classification among the anxiolytic agents. The initial negative result for zolpidem in the first study may indicate a less reliable anxiolytic action for this agent, although this could not be resolved as attributable to drug history.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10805613     DOI: 10.1007/s002139900354

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  8 in total

1.  Effects of zolpidem on sedation, anxiety, and memory in the plus-maze discriminative avoidance task.

Authors:  Karina A Zanin; Camilla L Patti; Leandro Sanday; Luciano Fernandes-Santos; Larissa C Oliveira; Dalva Poyares; Sergio Tufik; Roberto Frussa-Filho
Journal:  Psychopharmacology (Berl)       Date:  2012-06-23       Impact factor: 4.530

2.  Bidirectional effects of benzodiazepine binding site ligands on active avoidance acquisition and retention: differential antagonism by flumazenil and beta-CCt.

Authors:  Miroslav M Savić; Dragan I Obradović; Nenad D Ugresić; James M Cook; P V V S Sarma; Dubravko R Bokonjić
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

Review 3.  The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.

Authors:  Amanda C Fitzgerald; Brittany T Wright; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

4.  Impact of zaleplon on continuous positive airway pressure therapy compliance.

Authors:  John G Park; Eric J Olson; Timothy I Morgenthaler
Journal:  J Clin Sleep Med       Date:  2013-05-15       Impact factor: 4.062

5.  Enhanced sucrose pellet consumption induced by benzodiazepine-type drugs in squirrel monkeys: role of GABAA receptor subtypes.

Authors:  Angela N Duke; Donna M Platt; James M Cook; Shengming Huang; Wenyuan Yin; Bruce A Mattingly; James K Rowlett
Journal:  Psychopharmacology (Berl)       Date:  2006-06-17       Impact factor: 4.530

6.  Influence of diltiazem on the behavior of zolpidem-treated mice in the elevated-plus maze test.

Authors:  X-Y Cui; X Zhao; Q-P Chu; B-Q Chen; Y-H Zhang
Journal:  J Neural Transm (Vienna)       Date:  2006-08-01       Impact factor: 3.575

7.  Benzodiazepines and heightened aggressive behavior in rats: reduction by GABA(A)/alpha(1) receptor antagonists.

Authors:  Shannon L Gourley; Joseph F Debold; Wenyuan Yin; James Cook; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2004-08-17       Impact factor: 4.530

Review 8.  Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone.

Authors:  David R Drover
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.